Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
There are many anticancer drugs used clinically that can destroy DNA's structure, affect the gene control function and gene expression of DNA through binding with DNA in cancerous cells and demonstrating their anticancer activation. Therefore, it is very important to study the interaction of DNA with anticancer drugs not only for elucidating the action mechanisms of some antitumour drugs, but also for designing the new-type of anticancer drugs. BleomycinA5 (BLMA5) belongs to a family of glycopeptide-derived antitumour originally isolated from cultures of Streptomyces verticillus. It is one of the bleomycins antibiotics, which has more activity, lower toxicity and is widely used for the clinical treatment of a variety of cancers, notably squamous cell carcinomas, testicular tumors and malignant lymphomas.